Today, we are publishing the Enterprise IT section of our 29th Tech Infrastructure Quarterly Bible. The Tech Bible is a must-read for any tech investor, as it summarizes the quarterly earnings reports from the over 140 companies we track, providing an update on our key perspectives and convictions. Legacy IT spending is stabilizing after a strong 2H24, while public-cloud growth accelerates on broad-based strength across AI and traditional workloads. SaaS revenue growth remains in the low-teens ...
Today, we are publishing the Telecom Infrastructure section of our 29th Tech Infrastructure Quarterly Bible. The Tech Bible is a must-read for any tech investor, as it summarizes the quarterly earnings reports from the over 140 companies we track, providing an update on our key perspectives and convictions. Fixed equipment revenues are rebounding from the inventory correction, rising 11% YoY. RAN revenues declined 1% YoY, reflecting the ongoing weak demand following the 5G cycle. Telecom semis ...
A director at Palo Alto Networks Inc sold 25,000 shares at 195.202USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
L’Agence des médicaments du Canada émet une recommandation positive pour le remboursement de SKYRIZI® (risankizumab) pour le traitement de la colite ulcéreuse, et AbbVie conclut une lettre d’intention avec l’Alliance pharmaceutique pancanadienne SKYRIZI®, un inhibiteur de l’interleukine 23 (IL-23), a fait l’objet de deux recommandations consécutives de l’Agence des médicaments du Canada (AMC) visant son remboursement pour le traitement des maladies inflammatoires de l’intestin, initialement pour la maladie de Crohn et maintenant pour la colite ulcéreuse. Ces recommandations s’appuient sur l...
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2AbbVie c...
Lancement du Prix AbbVie des innovateurs en biotechnologies au Québec : AbbVie et adMare BioInnovations encouragent l’innovation dans le domaine des sciences de la vie Le lancement d’un concours national, en collaboration avec adMare BioInnovations, illustre l’engagement d’AbbVie à favoriser le dynamisme de l’écosystème des biotechnologies au Québec.L’entreprise biotechnologique lauréate se verra offrir gratuitement pendant un an des espaces de laboratoire et de bureau au Centre d’innovation adMare, ainsi que du matériel et des services partagés, et bénéficiera du soutien et du mentorat de ...
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec One biotech will receive a year of laboratory and office space including access to shared equipment and services at no cost at the adMare Innovation Centre in Montreal, as well as access to AbbVie's scientific and business executives support and mentorshipApplications will be accepted until February 20, 2026. MONTREAL, Nov...
A Closer Look at FY1Q26 (October) ResultsRevenueTotal revenue of $2.474 billion (up 16% y/y) came in above the company’s guidance range for revenue of $2.450 billion and $2.470 billion and above the Street’s $2.460 billion estimate fueled by growth in software firewalls, PAN-OS, and SD-WAN.Product
Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.